Zobrazeno 1 - 10
of 10
pro vyhledávání: '"L Borràs Trias"'
Publikováno v:
Section 7: Post Congress additions.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a28ff1ed316f94e1a2cc7a376ea61af8
https://doi.org/10.1136/ejhpharm-2022-eahp.396
https://doi.org/10.1136/ejhpharm-2022-eahp.396
Autor:
A Sosa-Pons, P Monzó Gallo, R Rodriguez Mauriz, N Rudi Sola, AA Villagrasa Vilella, L Borràs Trias, N Almendros-Abad
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Human serum albumin (HSA) is widely used in clinical practice, although many indications are still being debated. Aim and objectives To analyse the clinical indications for HSA and the level of evidence for them. Material an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4288db5f0da84adf3475d244c18195be
https://doi.org/10.1136/ejhpharm-2021-eahpconf.59
https://doi.org/10.1136/ejhpharm-2021-eahpconf.59
Autor:
N Almendros-Abad, L Borràs Trias, R Rodriguez Mauriz, C Seguí Solanes, N Rudi Sola, MA Pérez-Quirós, MA Aldirra-Taha, A Planas-Giner
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background Neutropaenia is one of the most common adverse effects of paclitaxel. It is dose-dependent and has dose-limiting toxicity. However, the American Society of Clinical Oncology (ASCO) guideline recommends the use of real bodyweight for chemot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::321ee677c1a249665c12c9259c30db2d
https://doi.org/10.1136/ejhpharm-2019-eahpconf.496
https://doi.org/10.1136/ejhpharm-2019-eahpconf.496
Autor:
Aldirra-Taha, N Almendros Abad, C Seguí Solanes, L Borràs Trias, N Rudi Sola, MA Pérez-Quirós, R Rodriguez Mauriz, A Planas-Giner
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background The use of panitumumab in the treatment of metastatic colorectal cancer (mCRC) remains controversial because of its risk/benefit profile. Purpose The aim of this study was to investigate the efficacy and safety of panitumumab in patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a1bd242d21e3f5a7b7c619b5c1bf66b
https://doi.org/10.1136/ejhpharm-2019-eahpconf.479
https://doi.org/10.1136/ejhpharm-2019-eahpconf.479
Autor:
M Gómez-Valent, M Cirera i Perich, L Borràs Trias, S Ortonobes Roig, B Mañé Velilla, MQ Gorgas Torner
Publikováno v:
Patient safety and risk management.
Background Chronic treatment revisions optimise drug treatment and prevent potential drug related problems. Therefore, we started a new healthcare model based on multidisciplinary team work, integrated and focused on the patient. This programme is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6a5c5db801f90a3a32cc5724930745b
https://doi.org/10.1136/ejhpharm-2017-000640.561
https://doi.org/10.1136/ejhpharm-2017-000640.561
Autor:
Milagros García-Peláez, L Borràs Trias, MQ Gorgas Torner, M Florit Sureda, G Puig Comas, P Miralles Albors
Publikováno v:
Patient safety and risk management.
Background One of the objectives of the Health Department of Catalonia (Spain) is the clinical review of medications in chronic complex patients (CCP) and patients with advanced disease (PAD). The reconciliation and validation of treatments to detect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbe67feb891e4f59a83b55e85f01d49c
https://doi.org/10.1136/ejhpharm-2017-000640.537
https://doi.org/10.1136/ejhpharm-2017-000640.537
Publikováno v:
European Journal of Hospital Pharmacy. 23:A80.2-A81
Background Hospital pharmacists validate many treatments per day, mostly not knowing the hospitalised patient’s current situation and with little interaction with the medical team and nurses who care for these patients. Purpose To describe differen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2026955260e84d5709e84fd81d1f2ad7
https://doi.org/10.1136/ejhpharm-2016-000875.182
https://doi.org/10.1136/ejhpharm-2016-000875.182
Autor:
MQ Gorgas Torner, L Ortiz Ruiz, A Estefanell Tejero, E Oliver Ferrer, L Borràs Trias, C. Pontes García, N Rudi Sola, L Raich Montiu, M De Castro Julve
Publikováno v:
European Journal of Hospital Pharmacy. 22:A109.1-A109
Background Tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) is a recently-marketed fixed-dose combination of antiretrovirals with which there is little clinical experience as yet. Purpose To describe our clinical experience with TDF/FTC/RPV, in term
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0a375c47891b1590d0c2d1c066db429
https://doi.org/10.1136/ejhpharm-2015-000639.262
https://doi.org/10.1136/ejhpharm-2015-000639.262
Autor:
M. García Argelaguet, MQ Gorgas Torner, L Borràs Trias, L Raich Montiu, C. Pontes García, M De Castro Julve
Publikováno v:
European Journal of Hospital Pharmacy. 22:A108.2-A109
Background It has been repeatedly reported that up to 7% of patients have serious adverse drug reactions (ADR) during hospital admissions. Hospital-based pharmacovigilance aims to detect previously unknown serious ADRs arising during differential dia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d211fa544a073699893c52e0995b207
https://doi.org/10.1136/ejhpharm-2015-000639.261
https://doi.org/10.1136/ejhpharm-2015-000639.261
Autor:
Milagros García-Peláez, MQ Gorgas Torner, M. Cabré Serres, L Borràs Trias, M Gómez-Valent, L Raich Montiu, ML Iglesias Lepine, M De Castro Julve, M Payés Peich
Publikováno v:
European Journal of Hospital Pharmacy. 21:A145.2-A145
Background Clinical safety is an essential component of health care quality. The EVADUR study showed that 12% of patients who were in the emergency department (ED) had adverse events (AE). 70% of them were considered avoidable. Purpose To describe ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d63a4f655bab29a693b0a246ef7c7ebb
https://doi.org/10.1136/ejhpharm-2013-000436.356
https://doi.org/10.1136/ejhpharm-2013-000436.356